Balyasny Asset Management
PHAT icon

Balyasny Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Balyasny Asset Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Sell
95,301
-111,784
-54% -$1.41M ﹤0.01% 2054
2025
Q4 		$3.44M Sell
207,085
-88,076
-30% -$1.26M ﹤0.01% 1591
2025
Q3 		$3.47M Buy
295,161
+281,979
+2,139% +$2.91M ﹤0.01% 1550
2025
Q2 		$126K Sell
13,182
-32,649
-71% -$181K ﹤0.01% 2666
2025
Q1 		$287K Buy
+45,831
New +$278K ﹤0.01% 2466
2024
Q4 		– Sell
-65,659
Closed -$1.19M – 3150
2024
Q3 		$1.19M Buy
65,659
+50,653
+338% +$708K ﹤0.01% 1894
2024
Q2 		$155K Buy
+15,006
New +$155K ﹤0.01% 2374
2022
Q4 		– Sell
-18,532
Closed -$205K – 3128
2022
Q3 		$205K Buy
+18,532
New +$177K ﹤0.01% 2305

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.08B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return